RESEARCH PROOF- EDTA CHELATION WORKS

From: http://www.arteryhealthinstitute.com/?gclid=CKat4KDcqqECFQ1biAod7inXDg#HOW_DOES_IT_WORK

In the 1950's, EDTA was first used for clinical use in Michigan to treat battery factory workers who were suffering from lead poisoning. Following the treatment, the patients who were suffering from angina and coronary artery disease symptoms dropped dramatically. Additional studies were commenced to study these effects.
In 1955, research conducted at providence Hospital in Detroit, Michigan, found that EDTA dissolves “metastatic calcium” i.e. calcium that has been deposited where it is not wanted, namely arteries, joints, kidneys and even the bones in the inner ear. Chelation therapy appeared to be a powerful antidote to- and preventative against-atherosclerosis, arthritis, kidney stones and otosclerosis (hearing loss related to the calcification of the bones in the ear)
The first systemic study of EDTA in people with Atherosclerosis was published in 1956. Twenty patients with confirmed heart disease were given a series of 30 EDTA treatments intravenously. Nineteen of the patients experienced improvement, as measured by an increase in physical activity and in another study conducted four years later, a similar group found that three months of EDTA infusions caused decreases in the severity and frequency of anginal episodes, reduced use of nitroglycerin, increased work capacity and improved Electrocardiogram results
Since these early studies, hundreds of papers have been published on the favorable effects of chelation therapy in a variety of chronic diseases.
There have been two massive meta analyses of published and unpublished studies evaluating the results of over 24,000 chelation patients. The results: 88 percent of the patients demonstrated clinical improvement. 4
One other study included 92 patients who were referred for surgical intervention. At the end of the study, only 10 required surgery either during or after their chelation therapy. 5 In another study of 2,870 patients with various degrees of degenerative diseases, especially vascular disease, almost 90% of the patients showed excellent improvement. 6 In one small, controlled crossover study of patients with peripheral vascular disease, results showed significant improvements in walking distance and ankle/brachial blood flow. 7
And when, in one study, 65 patients on the waiting list for CABG surgery (for a mean of 6 months) were treated with EDTA chelation therapy — the symptoms in 89% improved so much, they were able to cancel their surgery. In the same study, of 27 patients recommended for limb amputation due to poor peripheral circulation, EDTA chelation resulted in saving 24 limbs. 8
It soon became clear from these and later studies that EDTA treatments result in progressive and widespread improvement and stabilization of cardiovascular function. This is in contrast to standard treatments, such as angioplasty or CABG, which instantaneously restore normal function in the few treated arteries, but leave the rest of the body completely untreated (there's every reason to believe that if arteries are clogged in the heart, they're also clogged in other vital organs, like the kidneys and brain). High-tech treatments for heart disease, such as angioplasty and CABG, long hailed as medical breakthroughs, are in fact, oversold, overpriced, and ineffective, especially when compared with EDTA chelation. The truth of this assertion has been demonstrated on numerous occasions over the last 2 decades:
The average mortality for CABG surgery is 4% to 10%. 9,10 In fact, CABG has no overall effect on improving survival. According to one study published in the New England Journal of Medicine, "As compared with medical therapy, coronary artery bypass surgery appears neither to prolong life nor to prevent myocardial infarction in patients who have mild angina or who are asymptomatic after infarction in the five-year period after coronary angiography." 11 By contrast, mortality rates for EDTA chelation, when carried out according to accepted protocols, approaches 0%. 12
Grafted coronary arteries are more than 10 times as likely to close up again within 3 years compared with coronary arteries that are not replaced with a graft. 13 Improved blood flow following EDTA chelation therapy is permanent as long as regular EDTA therapy (either oral or I.V.) is maintained.
Significant cerebral dysfunction, especially in older patients, is commonly seen following CABG. 14 Because EDTA chelation restores blood flow to the brain, it often results in improved cognition and memory. 15
Atherosclerosis is typically a body-wide disease. If your coronary arteries are occluded, it's a safe bet that arteries in your brain, kidneys, lungs, and other vital organs are also occluded. Angioplasty or CABG can clean out only a few arteries supplying the heart.
Virtually every study that has looked at the efficacy of EDTA chelation in vascular disease has demonstrated significant clinical improvement
INTRAVENOUS VS. ORAL EDTA
Oral EDTA has been used for at least as long as its IV cousin. Intravenous EDTA chelation has a direct and powerful effect on the body almost instantaneously. Not as convenient as swallowing a few capsules of oral EDTA per day, an IV EDTA session usually lasts about 3 hours, during which about 1000 mg to 3,000mg of EDTA (plus vitamin C and other nutrients) are administered. The number of treatments necessary (generally about 20 to 50 sessions) depends on the individual’s condition. Typical candidates for IV chelation are people who have been diagnosed with serious atherosclerosis, heavy metal poisoning, or symptoms of vascular occlusion or significant calcification of tissues. A series of needed sessions of IV EDTA will cost about $2,000 to $4,000. Oral EDTA chelation costs significantly less, about $49 a month.
In 1954, Dr. Harry Foreman and his colleagues performed a landmark study to determine how much orally administered EDTA the body absorbs. The scientists found that the body absorbs approximately 5% of orally consumed EDTA and that it can take up to three days for the EDTA to be totally excreted. If someone consumed nutritional supplements that contained 500mg of EDTA, then we can assume from Dr. Foreman’s research that about 25mg will be absorbed each day and that 750mg will be absorbed each month. That equates to almost the same amount of EDTA administered in one intravenous chelation treatment using a low-dose optimum protocol and affirms oral EDTA’s effectiveness over time.
LIQUID VS CAPSULES